Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.40 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.40 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 2/20 | 0.39 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP7 | P09237 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401639 | 0.92 | FKBP1A (0.41) | NPC1RAB9AMEN1ALDH1A1KMT2A | |
| SCHEMBL698250 | 0.91 | NPC1 (0.44) | NPC1RAB9AFKBP1ANCOA1NCOA3 | |
| SCHEMBL3442356 | 0.89 | FKBP1A (0.44) | NPC1RAB9AFKBP1AHTR7TMEM97 | |
| SCHEMBL639468 | 0.87 | HTR7 (0.41) | NPC1RAB9AFKBP1AHTR7TMEM97 | |
| SCHEMBL639859 | 0.87 | NPC1 (0.42) | NPC1RAB9AFKBP1ANCOA1NCOA3 | |
| SCHEMBL3446456 | 0.87 | RAB9A (0.43) | NPC1RAB9AFKBP1AMMP1MMP3 | |
| SCHEMBL2753547 | 0.86 | RAB9A (0.46) | NPC1RAB9AFKBP1ANCOA1NCOA3 | |
| SCHEMBL4404580 | 0.86 | PSEN1 (0.46) | NPC1RAB9AFKBP1AHTR7TMEM97 | |
| SCHEMBL639201 | 0.85 | NPC1 (0.42) | NPC1RAB9AALDH1A1FKBP1AHTR7 | |
| SCHEMBL10205747 | 0.85 | NPC1 (0.41) | NPC1RAB9AFKBP1ANCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8318769-B2 | Substituted sulfonamide compounds | GRUENETHAL GMBH (DE) | 2012-11-27 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-8124624-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-28 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090264407-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-22 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264407-A1 | Substituted Sulfonamide Compounds | CNR1, SUCNR1, OPRL1 | NPC1 1598/4885RAB9A 2243/4885MEN1 3536/4885 |
| US-20090253669-A1 | Substituted Sulfonamide Compounds | SULT2A1, STS, SULT1A1 | NPC1 2399/4885RAB9A 2485/4885MEN1 2751/4885 |
| US-20090264400-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | NPC1 2705/4885RAB9A 3451/4885MEN1 2417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.